Clinical Trials

Inclusion Criteria

• NYHA class II-IV heart failure due to ischemic or non-ischemic cardiomyopathy
• Left ventricular ejection fraction ≤ 40% by echocardiography
• Heart failure symptoms for 3 months despite standard treatment
• Serum uric acid level ≥ 9.5 mg/dl
• At least one of the following additional markers of increased risk
  • Hospitalization
  • ER visit or urgent clinic visit for heart failure requiring IV diuretics within the previous 12 months
  • Left ventricular ejection fraction ≤ 25
  • B-type natriuretic peptide level > 250 pg/ml

Exclusion Criteria

• Hypertrophic or restrictive cardiomyopathy, constrictive pericarditis, biopsy-proven myocarditis, severe stenotic valvular disease, or complex congenital heart disease
• Acute coronary syndrome, PCI or CABG within 3 months
• Current ventricular assist device or ventricular assist device or heart transplant likely within the next 6 months
• Uncontrolled hypertension (i.e., SBP > 170 mm Hg or DBP > 110 mm Hg)
• Serum creatinine > 3 mg/dL or estimated GFR < 20 ml/min
• Evidence of active hepatitis with ALT and AST greater than 3x normal
• Any condition other than HF which could limit the ability to perform a 6-minute walk test
• Any diseases other than HF which are likely to alter the patient's global perception of status or quality of life over a period of 6 months
• Receiving treatment with allopurinol currently or within 30 days, or having symptomatic hyperuricemia which requires treatment with allopurinol